Kisqali Plus Hormone Therapy for Metastatic Breast Cancer
WEBJan 11, 2023 · In pre- and perimenopausal women with breast cancer, combining ribociclib (Kisqali) and hormone therapy was more effective at halting the growth of metastatic tumors than standard treatment with a combination of chemotherapy drugs.
Novartis Kisqali® significantly reduced the risk of recurrence by …
WEBJun 2, 2023 · Kisqali is the first and only CDK4/6 inhibitor to demonstrate a consistent, clinically meaningful benefit across a broad population of patients with HR+/HER2- early breast cancer, regardless of disease stage, menopausal or nodal status1.
Novartis Kisqali® prolonged PFS benefit for pre- and …
WEBDec 6, 2022 · Kisqali demonstrated a nearly one-year progression-free survival (PFS) benefit in the study, supporting the superiority of Kisqali plus ET for this hard-to-treat patient population.
Latest Novartis Kisqali® NATALEE analysis reinforces 25
WEBDec 8, 2023 · NATALEE is a global Phase III multi-center, randomized, open-label trial to evaluate the efficacy and safety of Kisqali ® (ribociclib) with ET as an investigational adjuvant treatment versus ET...
Adding Ribociclib to Hormonal Therapy Reduces Risk of …
WEBAdding the targeted therapy drug ribociclib (Kisqali®) to hormonal (endocrine) therapy showed a significant improvement in invasive disease-free survival (iDFS) for people with HR-positive, HER2-negative early-stage breast cancer.
eBC and mBC Treatment | KISQALI (ribociclib)
WEBLearn about HR+, HER2- metastatic breast cancer treatment in premenopausal and postmenopausal women with KISQALI. See full Prescribing & Safety Info.
ESMO: In landmark win, Novartis' Kisqali extends breast cancer …
WEBSep 19, 2021 · Novartis’ breast cancer drug Kisqali already has two clinical wins under its belt showing a survival benefit over traditional treatment. Now, the company hopes a third, first-of-its-kind victory...
Efficacy of KISQALI® (ribociclib) + AI in 1L Postmenopausal | HCP
WEBView MONALEESA-2 efficacy data for KISQALI in combination with an AI for 1L postmenopausal patients with HR+/HER2- mBC. See full Prescribing & Safety Info.
Breast cancer treatment: Drug Kisqali approval expanded for …
WEB3 days ago · In a phase 3 clinical trial from the drugmaker Novartis, Kisqali reduced the risk of a patient’s breast cancer coming back by 25% after three years when given in addition to standard treatments,...
Novartis Kisqali® reduced the risk of cancer recurrence while ...
WEBSep 14, 2023 · Updates to the NCCN Guidelines® for breast cancer, released in January 2023, recommend ribociclib (Kisqali) as the only Category 1 preferred CDK4/6 inhibitor for first-line treatment of patients with HR+/HER2- MBC when combined with …